Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K J Scanlon

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Antisense & Nucleic Acid Drug Development|August 27, 1999
Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancerA Irie, B Anderegg, M Kashani-Sabet, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 1, 1995
Oligonucleotide-mediated modulation of mammalian gene expressionK J Scanlon, Y Ohta, H Ishida, et al.
Biochemical and Biophysical Research Communications|January 8, 1999
Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cellsT Tsuchida, H Kijima, Y Oshika, et al.
In Vivo (Athens, Greece)|November 1, 1993
Suppression of EJ cells tumorigenicityT Tone, M Kashani-Sabet, T Funato, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Oligonucleotide modulation of multidrug resistanceD Y Bouffard, T Ohkawa, H Kijima, et al.
Advances in Pharmacology (San Diego, Calif.)|January 1, 1997
Anti-oncogene ribozymes for cancer gene therapyA Irie, H Kijima, T Ohkawa, et al.
Journal of Medicinal Chemistry|May 1, 1986
Synthesis and biological activity of several amino nucleoside-platinum(II) complexesT S Lin, R X Zhou, K J Scanlon, et al.
Cancer Gene Therapy|April 15, 2000
Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinomaT Tsuchida, H Kijima, S Hori, et al.
Cancer Research|December 1, 1996
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozymeG M Maelandsmo, E Hovig, M Skrede, et al.
Cancer Research|June 1, 1992
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexateB T Hill, S A Shellard, L K Hosking, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Antisense & Nucleic Acid Drug Development|August 27, 1999
Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancerA Irie, B Anderegg, M Kashani-Sabet, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|October 1, 1995
Oligonucleotide-mediated modulation of mammalian gene expressionK J Scanlon, Y Ohta, H Ishida, et al.
Biochemical and Biophysical Research Communications|January 8, 1999
Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cellsT Tsuchida, H Kijima, Y Oshika, et al.
In Vivo (Athens, Greece)|November 1, 1993
Suppression of EJ cells tumorigenicityT Tone, M Kashani-Sabet, T Funato, et al.
European Journal of Cancer (Oxford, England : 1990)|June 1, 1996
Oligonucleotide modulation of multidrug resistanceD Y Bouffard, T Ohkawa, H Kijima, et al.
Advances in Pharmacology (San Diego, Calif.)|January 1, 1997
Anti-oncogene ribozymes for cancer gene therapyA Irie, H Kijima, T Ohkawa, et al.
Journal of Medicinal Chemistry|May 1, 1986
Synthesis and biological activity of several amino nucleoside-platinum(II) complexesT S Lin, R X Zhou, K J Scanlon, et al.
Cancer Gene Therapy|April 15, 2000
Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinomaT Tsuchida, H Kijima, S Hori, et al.
Cancer Research|December 1, 1996
Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1) ribozymeG M Maelandsmo, E Hovig, M Skrede, et al.
Cancer Research|June 1, 1992
Characterization of a cisplatin-resistant human ovarian carcinoma cell line expressing cross-resistance to 5-fluorouracil but collateral sensitivity to methotrexateB T Hill, S A Shellard, L K Hosking, et al.
Pageof 9